Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 16, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing details changes in the holdings of the GlaxoSmithKline US Retirement Savings Plan ("the Plan"), a discretionary fund for employees and former employees. Two directors, Dr. J-P Garnier and Dr. M M Slaoui, are noted as potentially interested in the shares held in the fund. The specific movements were:
- January 11, 2007: Holdings decreased from 17,140,684 to 17,004,809 Ordinary Share ADRs at an average price of $54.72.
- January 12, 2007: Holdings increased from 17,004,809 to 17,028,609 Ordinary Share ADRs at an average price of $53.07.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly addresses compliance with Disclosure Rule 3.1.4R(1)(b) regarding the reported transactions.
Key Facts for Investor Verification
- Verify the total aggregate holdings of the GlaxoSmithKline US Retirement Savings Plan following the January 12 transaction (17,028,609 ADRs).
- Confirm the potential interest of Directors Dr. J-P Garnier and Dr. M M Slaoui in the fund's holdings.
- Note the average transaction prices of $54.72 and $53.07 for the respective dates.